false 0001739174 0001739174 2025-02-27 2025-02-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 27, 2025

 

BiomX Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-38762   82-3364020
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

22 Einstein St., Floor 4

Ness Ziona, Israel

   74140003
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +972 723942377

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   PHGE   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 8.01 Other Events.

 

As previously disclosed, on February 25, 2025, BiomX Inc. (the “Company”) entered into a series of transactions including a registered direct offering, a concurrent private placement, and the exercise of certain exisiting warrants (collectively, the “Offering”). The aggregate gross proceeds to the Company from the Offering were approximately $12 million, before deducting placement agent fees and other offering expenses payable by the Company. The Offering closed on February 27, 2025. Following the closing of the Offering, as of March 5, 2025, the Company has 24,996,053 shares of its common stock issued and outstanding.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 5, 2025 BiomX Inc.
   
  By: /s/ Jonathan Solomon
    Name:  Jonathan Solomon
    Title: Chief Executive Officer

 

2

 

 

 

 

 

v3.25.0.1
Cover
Feb. 27, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 27, 2025
Entity File Number 001-38762
Entity Registrant Name BiomX Inc.
Entity Central Index Key 0001739174
Entity Tax Identification Number 82-3364020
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 22 Einstein St.
Entity Address, Address Line Two Floor 4
Entity Address, City or Town Ness Ziona
Entity Address, Country IL
Entity Address, Postal Zip Code 74140003
City Area Code 972
Local Phone Number 723942377
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol PHGE
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
BiomX (AMEX:PHGE)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025 Click aqui para mais gráficos BiomX.
BiomX (AMEX:PHGE)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025 Click aqui para mais gráficos BiomX.